(MedPage Today) — Investigational delpacibart etedesiran (del-desiran) showed promise in the phase I/II MARINA trial of myotonic dystrophy type 1 (DM1), a rare progressive disorder caused by a toxic gain-of-function mutation in the DM1 protein…
Source link : https://www.medpagetoday.com/neurology/generalneurology/119937
Author :
Publish date : 2026-02-18 22:00:00
Copyright for syndicated content belongs to the linked Source.
